住院COVID-19患者的代谢综合征与急性呼吸窘迫综合征
该多中心队列研究纳入26国181家医院2020年2月15日至2021年2月18日收治的29404例成人COVID-19住院患者,比较合并代谢综合征(肥胖、糖尿病前期或糖尿病、高血压、血脂异常中≥3项)者与无代谢综合征者的结局。调整分析显示,代谢综合征与ICU入住(aOR 1.32)、有创机械通气(aOR 1.45)、ARDS(aOR 1.36)及死亡(aOR 1.19)风险升高相关,住院时间和ICU时间亦延长。代谢综合征标准每增加1项,ARDS风险呈累积性升高。提示临床对合并代谢综合征的COVID-19住院患者应加强呼吸与重症风险监测。
要点
- 合并代谢综合征的COVID-19住院患者死亡风险升高(aOR 1.19,95%CI 1.08-1.31),ICU入住风险升高(aOR 1.32,95%CI 1.14-1.53)。
- 代谢综合征与有创机械通气风险升高相关(aOR 1.45,95%CI 1.28-1.65),与ARDS风险升高相关(aOR 1.36,95%CI 1.12-1.66)。
- 代谢综合征患者住院时间中位数8.0天 vs 无代谢综合征者6.8天(P < .001),ICU时间中位数7.0天 vs 6.4天(P < .001)。
- 代谢综合征标准数量与ARDS风险呈累积关联:1项10.4%(P = .83)、2项15.3%(P < .001)、3项19.3%(P < .001)、4项24.3%(P < .001)。
适用人群与场景
- 成人COVID-19住院患者,且出院状态资料完整;研究期间为2020年2月15日至2021年2月18日,来自26个国家181家医院。
- 代谢综合征定义为以下标准中≥3项:肥胖、糖尿病前期或糖尿病、高血压、血脂异常。
诊断标准与关键阈值
- 代谢综合征诊断标准:肥胖、糖尿病前期或糖尿病、高血压、血脂异常4项中满足≥3项。
研究设计与关键结果
- 研究类型:多中心队列研究,使用重症医学学会Discovery病毒性呼吸道疾病通用研究数据,来自26国181家医院,纳入29404例成人COVID-19住院患者。
- 代谢综合征组5069例(17.5%)vs 无代谢综合征对照组23971例(82.5%);代谢综合征组平均(SD)年龄61.2(17.8)岁,女性13059例(45.0%),男性15713例(54.1%),黑人6797例(23.4%),西班牙裔5325例(18.3%),白人16507例(57.8%)。
- 调整分析:代谢综合征与ICU入住风险升高相关(aOR 1.32,95%CI 1.14-1.53),与有创机械通气风险升高相关(aOR 1.45,95%CI 1.28-1.65),与ARDS风险升高相关(aOR 1.36,95%CI 1.12-1.66),与死亡风险升高相关(aOR 1.19,95%CI 1.08-1.31)。
- 住院时间中位数(IQR):代谢综合征组8.0(4.2-15.8)天 vs 对照组6.8(3.4-13.0)天,P < .001;ICU时间中位数(IQR):代谢综合征组7.0(2.8-15.0)天 vs 对照组6.4(2.7-13.0)天,P < .001。
- 代谢综合征标准数量与ARDS风险呈累积关联:1项标准者ARDS 1147例(10.4%),P = .83;2项标准者ARDS 1191例(15.3%),P < .001;3项标准者ARDS 817例(19.3%),P < .001;4项标准者ARDS 203例(24.3%),P < .001。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,代谢综合征与COVID-19住院患者ARDS和死亡风险升高相关,且ARDS关联随代谢综合征标准数量累积。
- 对合并代谢综合征的COVID-19住院患者,应关注ICU入住、有创机械通气及ARDS风险,并注意住院和ICU时间可能延长。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Obesity, diabetes, and hypertension are common comorbidities in patients with severe COVID-19, yet little is known about the risk of acute respiratory distress syndrome (ARDS) or death in patients with COVID-19 and metabolic syndrome.
OBJECTIVE: To determine whether metabolic syndrome is associated with an increased risk of ARDS and death from COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study used data from the Society of Critical Care Medicine Discovery Viral Respiratory Illness Universal Study collected from 181 hospitals across 26 countries from February 15, 2020, to February 18, 2021. Outcomes were compared between patients with metabolic syndrome (defined as ≥3 of the following criteria: obesity, prediabetes or diabetes, hypertension, and dyslipidemia) and a control population without metabolic syndrome. Participants included adult patients hospitalized for COVID-19 during the study period who had a completed discharge status. Data were analyzed from February 22 to October 5, 2021.
EXPOSURES: Exposures were SARS-CoV-2 infection, metabolic syndrome, obesity, prediabetes or diabetes, hypertension, and/or dyslipidemia.
MAIN OUTCOMES AND MEASURES: The primary outcome was in-hospital mortality. Secondary outcomes included ARDS, intensive care unit (ICU) admission, need for invasive mechanical ventilation, and length of stay (LOS).
RESULTS: Among 46 441 patients hospitalized with COVID-19, 29 040 patients (mean [SD] age, 61.2 [17.8] years; 13 059 [45.0%] women and 15713 [54.1%] men; 6797 Black patients [23.4%], 5325 Hispanic patients [18.3%], and 16 507 White patients [57.8%]) met inclusion criteria. A total of 5069 patients (17.5%) with metabolic syndrome were compared with 23 971 control patients (82.5%) without metabolic syndrome. In adjusted analyses, metabolic syndrome was associated with increased risk of ICU admission (adjusted odds ratio [aOR], 1.32 [95% CI, 1.14-1.53]), invasive mechanical ventilation (aOR, 1.45 [95% CI, 1.28-1.65]), ARDS (aOR, 1.36 [95% CI, 1.12-1.66]), and mortality (aOR, 1.19 [95% CI, 1.08-1.31]) and prolonged hospital LOS (median [IQR], 8.0 [4.2-15.8] days vs 6.8 [3.4-13.0] days; P < .001) and ICU LOS (median [IQR], 7.0 [2.8-15.0] days vs 6.4 [2.7-13.0] days; P < .001). Each additional metabolic syndrome criterion was associated with increased risk of ARDS in an additive fashion (1 criterion: 1147 patients with ARDS [10.4%]; P = .83; 2 criteria: 1191 patients with ARDS [15.3%]; P < .001; 3 criteria: 817 patients with ARDS [19.3%]; P < .001; 4 criteria: 203 patients with ARDS [24.3%]; P < .001).
CONCLUSIONS AND RELEVANCE: These findings suggest that metabolic syndrome was associated with increased risks of ARDS and death in patients hospitalized with COVID-19. The association with ARDS was cumulative for each metabolic syndrome criteria present.
参考来源
- Denson JL, Gillet AS, Zu Y, et al. Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19. JAMA Netw Open. 2021. PMID: 34935924. doi:10.1001/jamanetworkopen.2021.40568
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。